Clin2
NCT07768371Possibly a fitRecruiting

Remibrutinib for peanut, milk, or egg allergies

IgE-Mediated Food AllergyPeanut AllergyCow Milk AllergyEgg Allergy

Treatments studied

Part of Immune system & allergy clinical trials.

This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
576 people
Ages
12 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 12 and 65 years old.
  • You must have a confirmed allergy to peanuts, milk, or eggs, shown by a blood test and a skin prick test.
  • You must have a positive food challenge at the start of the study, meaning you react to a small amount of the allergen.
  • You must be willing to avoid the allergen (peanut, milk, or egg) and any other foods you are allergic to during the study.
  • You must not have used remibrutinib or other BTK inhibitors before.
  • You must be able to attend study visits and follow the study procedures.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07015996Recruiting· Phase 2
Tezepelumab for peanut allergy oral immunotherapy

This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.

Little Rock, Arkansas
NCT04163562Recruiting· Phase 1/Phase 2
Oral peanut treatment trial for people with peanut allergy

This trial tests an oral (by mouth) immune treatment for people with confirmed peanut allergy. It aims to see whether your immune system can become less reactive to peanuts over time, while keeping you safe during testing with careful emergency planning.

Pamplona, Navarre
NCT06744920Recruiting· Phase 3
New drug for generalized myasthenia gravis

This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.

Phoenix, Arizona
NCT07220811Recruiting· Phase 2
Testing a new drug for food allergies

This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.

Phoenix, Arizona
NCT06865651Recruiting· Phase 2
Study of Remibrutinib for chronic hives not helped by antihistamines

This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.

North Miami Beach, Florida
NCT07700056Not yet recruiting· Phase 3
Study of remibrutinib for severe itching of unknown cause

This study tests an investigational medicine (remibrutinib) for people with severe itching that has no known cause. It may help reduce the itch when moisturizers haven't worked.

Hear when a new Peanut Allergy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.